1. Home
  2. S vs TWST Comparison

S vs TWST Comparison

Compare S & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SentinelOne Inc.

S

SentinelOne Inc.

HOLD

Current Price

$17.03

Market Cap

5.4B

Sector

Technology

ML Signal

HOLD

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$100.57

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
S
TWST
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.2B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
S
TWST
Price
$17.03
$100.57
Analyst Decision
Buy
Buy
Analyst Count
31
8
Target Price
$19.28
$46.88
AVG Volume (30 Days)
6.7M
2.1M
Earning Date
05-27-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
$1,001,278,000.00
$376,572,000.00
Revenue This Year
$22.84
$18.91
Revenue Next Year
$17.32
$15.07
P/E Ratio
N/A
N/A
Revenue Growth
21.89
20.32
52 Week Low
$11.81
$23.30
52 Week High
$21.40
$104.23

Technical Indicators

Market Signals
Indicator
S
TWST
Relative Strength Index (RSI) 61.20 78.45
Support Level $16.28 $42.88
Resistance Level $17.18 N/A
Average True Range (ATR) 0.69 5.82
MACD 0.18 1.68
Stochastic Oscillator 90.22 91.13

Price Performance

Historical Comparison
S
TWST

About S SentinelOne Inc.

SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: